This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
September 23, 2020
Nordic Nanovector ASA – Key information regarding potential repair offering
September 23, 2020
Nordic Nanovector – Private placement successfully completed
September 22, 2020
Digital Therapies Help Frontline Workers Cope
September 21, 2020
Camel-IDS enters next stage with name change to PRECIRIX® and IND approval for CAM-H2 Phase I/II study
September 21, 2020
GenSight Biologics reports new analysis demonstrating statistically significant and clinically meaningful difference between visual outcomes in LUMEVOQ®-treated patients and natural history of Leber Hereditary Optic Neuropathy (LHON)
September 18, 2020
Aprea Therapeutics Promotes Gregory S. Wessels to Chief Commercial Officer and Announces Governance Changes
September 16, 2020
Strongbridge Biopharma plc Announces Pricing of Public Offering of Ordinary Shares
September 15, 2020
GenSight Biologics Submits EU Marketing Authorisation Application for LUMEVOQ® Gene Therapy to Treat Vision Loss due to Leber Hereditary Optic Neuropathy (LHON)
September 14, 2020
Orexo commences patent infringement litigation against Sun Pharmaceutical
September 09, 2020
Orexo and GoGoMeds Partner to Bring Digital Therapies to Populations Battling Addiction and Depression with Limited Support Options